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Abstract
Background: The objective of this study was to evaluate the distribution of a series of independent doxycycline
inhibitory concentration 50% (IC50) values to validate the trimodal distribution previously described and to validate
the use of the pftetQ and pfmdt genes as molecular markers of decreased in vitro doxycycline susceptibility in
Plasmodium falciparum malaria.
Methods: Doxycycline IC50 values, from 484 isolates obtained at the French National Reference Centre for Imported
Malaria (Paris) between January 2006 and December 2010, were analysed for the first time by a Bayesian mixture
modelling approach to distinguish the different in vitro phenotypic groups by their IC50 values. Quantitative
real-time polymerase chain reaction was used to evaluate the pftetQ and pfmdt copy numbers of 89 African
P. falciparum isolates that were randomly chosen from the phenotypic groups.
Results: The existence of at least three doxycycline phenotypes was demonstrated. The mean doxycycline IC50
was significantly higher in the group with a pftetQ copy number >1 compared to the group with a pftetQ copy
number = 1 (33.17 μM versus 17.23 μM) and the group with a pfmdt copy number >1 (28.28 μM versus 16.11 μM).
There was a significant difference between the combined low and medium doxycycline IC50 group and the high
IC50 group in terms of the per cent of isolates with one or more copy numbers of the pftetQ gene (0% versus
20.69%) or pfmdt gene (8.33% versus 37.93%). In the logistic regression model, the pfmdt and pftetQ copy
numbers >1 (odds ratio = 4.65 and 11.47) were independently associated with the high IC50 group.
Conclusions: Copy numbers of pftetQ and pfmdt are potential predictive molecular markers of decreased
susceptibility to doxycycline.
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Background
Daily administration of doxycycline is currently a recom-
mended chemoprophylactic regimen for travellers visiting
malaria-endemic areas with high prevalence of chloro-
quine or multidrug resistance [1]. In addition, the French
malaria consensus recommends quinine and doxycycline
for the first-line treatment of Plasmodium falciparum se-
vere malaria in Asia and South America. In combination
with artesunate or quinine, doxycycline remains the rec-
ommendation as the second-line treatment of uncompli-
cated falciparum malaria or for the treatment of severe
malaria as a seven-day course [2]; however, its use is lim-
ited. Prophylactic failure of doxycycline against P. falcip-
arum has been associated with both inadequate doses [3]
and poor compliance [4].
Since September 2002, French troops have participated
in the peace-keeping operation, Operation Licorne, in
the Ivory Coast. Soldiers had been prescribed doxycycline
(100 mg) daily for prophylaxis. Many cases of malaria have
been reported, but most of these cases are believed to be
the result of poor compliance [5,6]. From 2002 to 2006,
1,787 falciparum malaria cases were observed in French
soldiers who were expected to take doxycycline. A surge
in the number of malaria cases within three weeks after
doxycycline prophylaxis discontinuation is often observed
after return [7,8]. Therefore, it is recommended that doxy-
cycline be taken for four weeks after returning from an
endemic area. However, resistance can also explain failures
of prophylactic doxycycline.
The ability to maximize the efficacy and longevity of
anti-malarial drugs for malaria control will depend crit-
ically on intensive research to identify in vitro markers
along with ex vivo and in vivo surveillance programmes.
It is necessary to identify molecular markers that predict
doxycycline resistance or decreased susceptibility in order
that active surveillance can monitor temporal trends in
parasite susceptibility [9]. Although there have been no re-
ported clinical failures for the treatment of falciparum
malaria with doxycycline, a Bayesian mixture modelling
approach has distinguished three different in vitro pheno-
typic groups: low, medium and high doxycycline IC50
values, among 747 P. falciparum isolates obtained from 14
African countries over a nine-year period [10]. The se-
quences of 11 P. falciparum genes that are analogous to
those involved in bacterial resistance to doxycycline were
obtained from 30 isolates from each phenotypic group.
The data suggested that the copy numbers of a tetQ
GTPase family gene, pftetQ (PFL1710c), and a metabolic
drug transporter gene, pfmdt (PFE0825w), were potential
molecular markers of decreased in vitro susceptibility to
doxycycline in African isolates [11].
The objective of this study was first to evaluate the
distribution of a new series of independent doxycycline
IC50 values assessed by another group for goodness of fit
with the trimodal compartment model of doxycycline re-
sponse previously proposed [10] and then to validate the
use of the pftetQ and pfmdt genes as molecular markers
of decreased in vitro susceptibility to doxycycline. This
was performed by assessing the gene copy numbers in P.
falciparum clinical isolates that were randomly chosen
from the phenotypic groups with different doxycycline
IC50 values.
Methods
Patients and sample collection
Between January 2006 and December 2010, 484 fresh P.
falciparum isolates were obtained at the French National
Reference Centre for Imported Malaria (Paris) from pa-
tients hospitalized with malaria after having returned to
France. These samples were successfully assessed for
doxycycline susceptibility. Ex vivo testing of doxycycline
susceptibility was performed as previously described by a
standard 42-hour 3H-hypoxanthine uptake inhibition assay
[12]. Batches of plates were tested and validated on the
chloroquine-susceptible 3D7 strain and the chloroquine-
resistant W2 strain.
The drug concentration that inhibited 50% parasite
growth (IC50) was calculated with the inhibitory sigmoid
Emax model, with estimation of the IC50 through non-
linear regression using a standard function of the R soft-
ware (ICEstimator) [13].
Quantification of pftetQ and pfmdt copy numbers
pfmdt (PFE0825w) and pftetQ (PFL1710c) copy numbers
were estimated by TaqMan real-time PCR (7900HT Fast
Real-Time PCR system, Applied Biosystems) relative to
the single-copy gene, pfβtubulin (PF10_0084). The follow-
ing oligonucleotide primers and probes were designed
using the Primer Express software v2.0 (Applied Biosys-
tems) for use in the polymerase chain reactions (PCRs):
5-TTATGCAAACATTTCAAGCTTCCT-3, 5- ACCC
ATTCCATAACTTAGATTTAGATAACC-3 and 5-VIC-
TAAAAACAAATTTCGACAAAAGGACAGGAGCC-TA
MRA-3 for pfmdt, 5-ACCCCTTTTTTATCTTACGAA
AG-3, 5-ATGGTTGTACGTTATATCATATGG-3 and
5-VIC-AAAAATGTGGCAACAATTCAGACATGTATC
A-TAMRA-3 for pftetQ and 5-TGATGTGCGCAAGT-
GATCC-3, 5-TCCTTTGTG GACATTCTTCCTC-3
and 5-FAM-TAGCACATGCCGTTAAATATCTTCCAT
GTCT-TAMRA-3 for pfβtubulin (Eurogentec). Individual
PCRs were performed using 1 X TaqMan Universal PCR
Master Mix (Applied Biosystems), 900 nM forward pri-
mer, 900 nM reverse primer, 250 nM TaqMan probe and
5 μL template DNA in a final volume of 25 μL The reac-
tion mixtures were prepared at 4°C in a 96-well optical re-
action plate (Applied Biosystems) covered with optical
adhesive covers (Applied Biosystems). The thermal cycling
conditions were 50°C for 2 min, 95°C for 10 min and
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50 cycles of 95°C for 15 sec and 60°C for 1 min. Each sam-
ple was assayed in triplicate and analysed with the SDS
software 2.2.1 (Applied Biosystems). The PCR efficiencies
of all the primer pairs were evaluated on a dilution series
of P. falciparum 3D7 genomic DNA. The efficiencies were
found to be sufficiently close to obviate the need for any
correction factor. Therefore, the 2-ΔΔCt method of rela-
tive quantification was used and adapted to estimate the
number of copies of the pfmdt and pftetQ genes [14,15]
with the formula ΔΔCt = (Ctpfmdt - Ctpfβtubulin) sample -
(Ctpfmdt  Ctpfβtubulin) calibrator. Genomic DNA extracted
from 3D7 P. falciparum, which has a single copy of each
gene, was used for calibration, whereas pfβtubulin
served as the control housekeeping gene in all the
experiments.
Genetic diversity of Plasmodium falciparum isolates with
pftetQ and pfmdt multicopies
Mixed infection could influence read-out in Taqman
real-time PCR, potentially leading to false positive re-
sults of gene copy number. The genomic DNA of P. fal-
ciparum isolates with at least two copies of pfmdt or
pftetQ were investigated for genetic diversity at highly
polymorphic loci, merozoite surface proteins 1 and 2
(MSP1 and MSP2). The msp1 and msp2 loci were geno-
typed using the nested PCR strategy and conditions pre-
viously described [16].
Statistical analysis
The statistical analysis has been designed to answer the
specific question of whether P. falciparum has different
doxycycline susceptibility phenotypes. A heterogeneous
population of IC50 values was observed; therefore, the
data were assumed to represent a univariate Gaussian
mixture with k components. Each observation was as-
sumed to originate from one of the k components, and
the label of the group from which each observation
arose was unknown. The unknowns of the model were
the number of components, the means, variances and
weights of the different components, and the vector of
allocations of the observations. The analysis was per-
formed in two steps. First, reversible jump Monte Carlo
Markov Chains (RJMCMC) [17] samplers were used to
choose a suitable number of components k, and the
present algorithm followed the recommendations of Cappé
et al. [18]. After a relevant number of components was
chosen, standard Gibbs samplers were run to obtain esti-
mates of the model parameters and to classify the observa-
tions [19]. Because of thelabel-switching problem, due to
the symmetry in the likelihood of the model parameters,
the mixture components should be labelled before making
an inference on the parameters [20]. The classical ordering
constraint, which was biologically relevant here, was used.
The algorithms were run for 5,000 burn-in iterations and
20,000 post-burn-in iterations. These numbers were as-
sumed to be sufficient to obtain reliable results. Moreover,
each algorithm was run three times to check that the re-
sults between two different runs were similar and that
there was no convergence problem [17].
The data were analysed using the R software® (version
2.10.1). The differences in the pfmdt and pftetQ copy
numbers between the phenotypic groups were tested
using the Mann Whitney test and the Kruskal-Wallis
test. The genotype proportions were compared using the
Fisher exact test. The risk of the high doxycycline IC50
was analysed using a logistic regression model (univari-
ate and multivariate analysis).
Ethics
Informed consent was not required for this study be-
cause the sampling procedures and testing are part of
the French national recommendations for the care and
surveillance of malaria.
Results
The doxycycline IC50 values ranged from 0.49 to 65.1 μM.
The mean was 11.64 μM (95% confidence interval, 10.96-
12.33). The average parameter estimates for the IC50
values by year are given in Table 1.
The triple normal distribution model is represented in
Figure 1. The parameter estimates for the three-component
mixture model, including the number of isolates in each
normal distribution, the mean of the IC50 values and the
standard deviation for each distribution, are summarised in
Table 2. A double normal distribution model and a quadru-
ple normal distribution model were also fitted to the data
to assess the validity of considering a three-component
mixture (data not shown). These two models fit the data
worse than the triple normal distribution model.
Eighty-nine P. falciparum isolates (30, 30 and 29) were
randomly chosen from the three phenotypic groups, A,
B and C, that differed in their doxycycline IC50 values.
These isolates were classified as follows: low doxycycline
IC50 group from component A [mean, 4.33 μM (95% CI,
3.39-4.37 μM)], medium doxycycline IC50 group from
component B [mean, 16.97 μM (95% CI, 16.45-17.49 μM)]
Table 1 Statistical analysis of the 484 doxycycline IC50
values by year
Year IC50 number Mean (μM) 95% CI IC50 min IC50 max
2006 119 10.05 9.14-10.96 0.63 43.7
2007 172 11.91 10.72-13.11 2.34 44.8
2008 59 9.45 8.56-10.35 4.27 23.1
2009 40 12.21 8.01-16.41 0.49 65.1
2010 94 14.3 12.63-15.97 4.55 46.2
Total 484 11.64 10.96-12.33 0.49 65.1
95% CI: 95% confidence interval.
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and high doxycycline IC50 group from component C
[mean, 34.60 μM (95% CI, 31.30-37.90 μM)].
Only one or two copies of pfmdt and pftetQ were iden-
tified in the 89 isolates. All of the isolates with two cop-
ies pfmdt or pftetQ had 1 allelic family for each of the
two genes (msp1 and msp2), confirming that these infec-
tions were single and not mixed. The mean doxycycline
IC50 was significantly higher in the group with a pftetQ
copy number >1 compared to the group with a pftetQ
copy number = 1 (33.17 μM versus 17.23 μM; P = 0.0041,
Mann Whitney test) (Table 3). The mean doxycycline
IC50 was significantly higher in the group with a pfmdt
copy number >1 (28.28 μM versus 16.11 μM; P = 0.0025,
MannWhitney test).
The number of pftetQ copies was significantly higher in
the high doxycycline IC50 group compared to the low and
medium doxycycline IC50 groups (1.21 versus 1.0 and 1.0;
P = 0.0014, Kruskal-Wallis test). The number of pfmdt
copies was significantly higher in the high doxycycline
IC50 group compared to the low and medium doxycycline
IC50 groups (1.38 versus 1.13 and 1.03, respectively; P =
0.0019, Kruskal-Wallis test).
There was no significant difference between the low
and medium doxycycline IC50 groups for the pfmdt and
pftetQ copy numbers. Therefore, these two phenotypic
groups were combined. There was a statistically signifi-
cant difference between the low and medium doxycyc-
line IC50 combined group and the high doxycycline
group in terms of the per cent of isolates with one or
more copy numbers of the pftetQ gene (0% versus 20.69%;
P = 0.0008, Fishers exact test) or pfmdt gene (8.33% versus
37.93%; P = 0.0021, Fishers exact test) (Table 4).
In the logistic regression model (Table 5), the pfmdt copy
number >1 (adjusted OR = 4.65 [1.31-16.51], P = 0.0176)
and pftetQ copy number >1 (adjusted OR = 11.47 [1.23-
106.98], P = 0.0322) were independently associated with
the high IC50 phenotypic group.
Discussion
Most prophylactic failures of doxycycline against P. falcip-
arum are associated with the use of standard doses result-
ing in lower than expected serum drug levels [21],
inadequate low doses [3], or poor compliance [4,22]. More-
over, doxycycline pharmacokinetic parameters could ex-
plain some of these cases. Doxycycline has a short
elimination half-life (16 hours) compared to proguanil
(24 hours), atovaquone (3173 hours), chloroquine (two to
Figure 1 Distribution of the doxycycline IC50 values of the 484
Plasmodium falciparum isolates (2006 to 2010) in the three-
component mixture model (Bayesian mixture modelling
approach). The dotted lines represent the three fitted mixtures.
Table 2 Parameter estimates for the three-component
mixture model for the 484 Plasmodium falciparum
isolates
Component Isolates number Proportion
(%)
IC50
mean (μM)
Standard
deviation
A 393 81.1 8.70 2.87
B 60 12.4 16.18 4.86
C 31 6.5 31.23 10.32
Table 3 Statistical analysis of the doxycycline IC50 values
based on the pftetQ and pfmdt copy numbers in 89
Plasmodium falciparum isolates
pftetQ copy number pfmdt copy number
= 1 > 1 = 1 > 1
Number of values 83 6 73 16
IC50 mean (μM) 17.23 33.17 16.11 28.28
Standard deviation 13.32 6.85 12.53 14.03
95% Confidence
interval
14.32-20.13 25.98-40.37 13.19-19.04 20.81-35.76
Minimal IC50 0.49 25.16 0.49 4.62
Maximal IC50 65.11 43.7 44.82 65.11
Table 4 Statistical analysis of pftetQ and pfmdt copy
numbers in 89 Plasmodium falciparum isolates (Fisher’s
exact test)
PftetQ Pfmdt
Low and
medium IC50
High IC50 Low and
medium IC50
High IC50
Copy number >1 0 6 5 11
Copy number = 1 60 23 55 18
% 0.00 20.69 8.33 37.93
Fisher’s exact test P value 0.0008 P value 0.0021
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three days), or mefloquine (six to 41 days), and a short
mean residence time (63% of the administered dose is
eliminated in 27 hours) [8]. In addition, its slow action
in vitro has a delayed effect upon growth and requires the
prolonged incubation of parasites [23]. Determination of
the IC50 after two generations of parasite growth decreases
the 42-hour IC50 from ten- to 20-fold [24,25]. However, in
practice, the standard 42-hour test remains the method of
monitoring doxycycline ex vivo susceptibility.
Maximizing the efficacy and longevity of anti-malarial
drugs to control malaria will critically depend on inten-
sive research to identify in vitro markers along with the
implementation of ex vivo and in vivo surveillance pro-
grammes, such as those championed by the WorldWide
Antimalarial Resistance Network [26]. Therefore, there
is a need to identify molecular markers that predict doxy-
cycline resistance, which can provide an active surveil-
lance method to monitor temporal trends in parasite
susceptibility [9]. In addition, the early detection of resist-
ance or decreased susceptibility to doxycycline will require
that the baseline parasite chemosusceptibility of current
isolates from endemic regions is established.
To validate the trimodal distribution model of doxy-
cycline IC50 values previously described for P. falcip-
arum African isolates [10], the distribution of a new
series of independent doxycycline IC50 values that were
assessed by a separate group under the same technical
conditions [12] was evaluated. This analysis was per-
formed with a Bayesian mixture modelling approach.
Again, the demonstration of the existence of at least three
doxycycline phenotypes was confirmed. All 484 values
were classified into three components: component A
(IC50 mean 8.7 μM), component B (IC50 mean 16.2 μM),
and component C (IC50 mean 31.2 μM). This trimodal
distribution model of doxycycline IC50 values from
imported P. falciparum isolates obtained from 2006 to
2010 confirms the previous data [10]. However, the level
of the IC50 value in each component is different between
the series of imported P. falciparum isolates obtained
from 2006 to 2010 and those obtained from 1999 to 2006
[10]. The IC50 doxycycline values from the isolates ob-
tained from 1999 to 2006 were classified into three
components: component A (IC50 mean 4.9 μM), compo-
nent B (IC50 mean 7.7 μM), and component C (IC50 mean
17.9 μM). It appears that components A and B (IC50
means 4.9 μM and 7.7 μM, respectively) for the values ob-
tained from 1999 to 2006 have merged into a single com-
ponent A (IC50 mean 8.7 μM) for the values obtained
from 2006 to 2010. In addition, the percentage of isolates
(78%) in the two components, A and B, for the values ob-
tained from 1999 to 2006 is similar to the percentage of
isolates (81%) for component A for the values obtained
from 2006 to 2010. The component B (IC50 mean
16.2 μM) values obtained from 2006 to 2010 correspond
to the component C (IC50 mean 17.9 μM) values obtained
from 1999 to 2006. A new component, component C
(IC50 mean 31.2 μM, proportion 6.4%), emerged for the
values obtained from 2006 to 2010. These data suggest the
emergence of strains with decreased susceptibility to
doxycycline. In addition, based on the previously defined
cut-off for reduced susceptibility to doxycycline (35 μM)
[10], 1.2% of the 747 P. falciparum isolates tested from
1999 to 2006 were considered to have decreased suscepti-
bility to doxycycline versus 2.7% for the 484 isolates tested
from 2006 to 2010.
Plasmodium falciparum possesses a tetQ GTPase fam-
ily gene analogue of the genes that encode bacterial ribo-
somal protection proteins. These genes are the pftetQ,
which is involved in bacterial resistance to the cycline
drugs, and a multidrug transporter gene, pfmdt, which
shares a high sequence identity with efflux pumps. In a
multivariate logistic regression model, an increased
pfmdt copy number was associated with high doxycyc-
line IC50 values with an adjusted odds ratio (OR) of 7.09
(p = 0.011), and an increased pftetQ copy number was
associated with an adjusted OR of 5.23 (p = 0.042) [11].
To validate the use of the pftetQ and pfmdt genes as mo-
lecular markers of decreased in vitro susceptibility to
doxycycline by assessing the gene copy numbers, 89 (30,
30 and 29) P. falciparum clinical isolates were randomly
chosen from the three phenotypic groups (A, B and C)
with different doxycycline IC50 values. These isolates were
classified as follows: low doxycycline IC50 group from
component A [mean, 4.33 μM (95% CI, 3.39-4.37 μM)],
Table 5 Multivariate regression model
Doxycycline IC50 group, number
Molecular marker Low or medium High Crude OR (95% CI) P Adjusted OR (95% CI) P
pftetQ copy number
1 60 23 1.00 (reference) 1.00 (reference)
> 1 0 6 18.77 (2.18-161.43) 0.0076 11.47 (1.23-106.98) 0.0322
pfmdt copy number
1 55 5 1.00 (reference) 1.00 (reference)
> 1 18 11 6.72 (2.06-21.96) 0.0016 4.65 (1.31-16.51) 0.0176
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medium doxycycline IC50 group from component B [mean,
16.97 μM (95% CI, 16.45-17.49 μM)] and high doxycycline
IC50 group from component C [mean, 34.60 μM (95% CI,
31.30-37.90 μM)]. These isolates were obtained from pa-
tients hospitalized with malaria after travel in Cameroon
(n = 18), Ivory Coast (n = 14), Mali (n = 11), Niger (n = 5),
Burundi (n = 4), Burkina Faso (n = 4), Djibouti (n = 4),
Madagascar (n = 4), Congo (n = 5), Ghana (n = 3), Sudan
(n = 2), Central African Republic (n = 2), Zambia (n = 1),
Rwanda (n = 1), Togo (n = 1), Guinea (n = 1), and nine
from Africa without specificity regarding the country.
The mean doxycycline IC50 value is significantly higher
in the groups with pftetQ or pfmdt copy numbers >1,
suggesting that pftetQ and pfmdt could be involved in
the reduced susceptibility to doxycycline.
The number of pftetQ and pfmdt gene copies is signifi-
cantly higher in the high doxycycline IC50 group than
the low and medium doxycycline IC50 groups. However,
there is no significant difference between the low and
the medium doxycycline IC50 groups for the pfmdt and
pftetQ copy numbers. These two phenotypic groups were,
therefore, combined. There is a statistically significant dif-
ference between the low and medium doxycycline IC50
combined group and the high doxycycline group in terms
of the per cent of isolates with one or more copy numbers
of the pftetQ gene (0% versus 20.69%; P = 0.0008) or pfmdt
gene (8.33% versus 37.93%; P = 0.0021). In addition, in the
multivariate logistic regression model, an increased pfmdt
copy number is associated with high doxycycline IC50
values with an adjusted OR of 4.65 (P = 0.0176), and an in-
creased pftetQ copy number is associated with an adjusted
OR of 11.47 (P = 0.0322). These results are consistent with
previous data [11] and confirm the potential use of pftetQ
and pfmdt as predictive molecular markers for decreased
P. falciparum susceptibility to doxycycline in Africa.
In a study on fresh P. falciparum clinical isolates from
Dakar, Senegal, it was shown that there was no statisti-
cally significant difference between a group with a doxy-
cycline IC50 <25 μM and a group with an IC50 >25 μM
in terms of the per cent of isolates with one or more
copy numbers of the pftetQ gene (p = 0.079) or pfmdt
gene (p = 0.066) [27]. However, the significance levels of
these associations were just above the P value threshold
(0.05). It seems that the number of isolates from the
high doxycycline IC50 group (15.9%) was most likely too
low to obtain statistically significant differences, indicating
the necessity of assessing the gene copy numbers with
more isolates. Another possibility is that over-expression
of pftetQ or pfmdt could confer in vitro reduced suscepti-
bility to doxycycline in association with other contributing
determinants, which could modulate the in vitro response
to doxycycline.
In summary, this study demonstrates that copy numbers
of the pftetQ and pfmdt genes are potential predictive
molecular markers of decreased P. falciparum susceptibil-
ity to doxycycline in Africa. Epidemiological studies using
large numbers of parasites with reduced susceptibility to
doxycycline are now required to determine whether pftetQ
and pfmdt can be used as markers of reduced in vitro
doxycycline susceptibility.
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